Point72 Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Point72 Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-217,500	Closed	-$2.26M	–	1369
2019 Q3	$2.26M	Sell	217,500 -301,370	-58%	-$3.94M	0.01%	576
2019 Q2	$7.95M	Buy	518,870 +343,870	+196%	+$4.97M	0.04%	421
2019 Q1	$2.25M	Sell	175,000 -125,000	-42%	-$1.41M	0.01%	688
2018 Q4	$2.85M	Buy	300,000 +40,000	+15%	+$519K	0.01%	665
2018 Q3	$4.32M	Buy	260,000 +45,000	+21%	+$721K	0.02%	633
2018 Q2	$3.45M	Sell	215,000 -35,000	-14%	-$625K	0.01%	681
2018 Q1	$3.83M	Buy	+250,000	New	+$3.9M	0.02%	629

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Point72 Asset Management's STML Position: Q4 2019 in Review

Point72 Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 217,500 shares — an estimated $2.26M sold.

Point72 Asset Management first reported a position in STML in Q1 2018 and held it in 7 quarters. The position peaked at $7.95M in Q2 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

Point72 Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Point72 Asset Management sold 217,500 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $2.26M.
Point72 Asset Management first reported a position in Stemline Therapeutics, Inc. in Q1 2018 and held it in 7 quarters.
Point72 Asset Management's Stemline Therapeutics, Inc. position peaked at $7.95M in Q2 2019.
99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.